Development of target delivery system based on actinomycin class drugs and recombinant alpha-fetoprotein


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A recombinant alpha-fetoprotein (rAFP) was obtained in the yeast P. pastoris system, and its functional activity was confirmed. A method for producing polymer particles loaded with dactinomycin was developed, and a conjugate of these nanoparticles with rAFP was synthesized. The efficiency of the obtained conjugate on the HeLa, SKOV3, and MG-63 tumor cells and the absence of toxicity on the normal cells was shown. Experiments in vivo demonstrated a significant increase in the antitumor efficacy of the conjugate at a lower general toxicity as compared to the commercially available dactinomycin.

About the authors

E. D. Nikolskaya

Russian Research Center for Molecular Diagnostics and Therapy

Author for correspondence.
Email: elenanikolskaja@gmail.com
Russian Federation, Moscow, 117149

O. A. Zhunina

Russian Research Center for Molecular Diagnostics and Therapy

Email: elenanikolskaja@gmail.com
Russian Federation, Moscow, 117149

N. G. Yabbarov

Russian Research Center for Molecular Diagnostics and Therapy

Email: elenanikolskaja@gmail.com
Russian Federation, Moscow, 117149

V. I. Shvets

Moscow State University of Fine Chemical Technologies (MITHT)

Email: elenanikolskaja@gmail.com
Russian Federation, Moscow, 119571

B. I. Krugliy

Russian Research Center for Molecular Diagnostics and Therapy

Email: elenanikolskaja@gmail.com
Russian Federation, Moscow, 117149

E. S. Severin

Russian Research Center for Molecular Diagnostics and Therapy

Email: elenanikolskaja@gmail.com
Russian Federation, Moscow, 117149

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Pleiades Publishing, Ltd.